Zimmer Biomet vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Zimmer Biomet (ZBH) reported ~$7.7B revenue in FY2024. Leading maker of orthopedic implants for knee and hip replacement surgeries, with robotics and digital surgery platforms. HQ: Warsaw, IN.
About
Zimmer Biomet Holdings, Inc. is one of the world's largest musculoskeletal healthcare companies, designing, manufacturing, and distributing orthopedic implants, spinal devices, dental implants, and surgical instrumentation. The company's core products are total knee and total hip replacement systems — the implants that allow surgeons to replace arthritic or damaged joints, enabling millions of patients to regain mobility and reduce chronic pain. Formed through Zimmer Holdings' $13.4 billion acquisition of Biomet in 2015, the company serves over 25 million patients annually.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.